On March 20, the fifth JD Health Partner Conference, themed“Seizing Momentum, Pioneering Innovation,”was held in Beijing. As a leading brand in the home nebulization industry, HOMED Medical has consistently focused on children's respiratory health for years. With its independently developed“JLN-2311HDD Plus Children's Nebulizer”series, the company has distinguished itself from numerous competitors, HOMED was honored with the “Breakthrough Award.” This accolade not only signifies high recognition of its technological leadership but also highlights the company's deep cultivation achievements in the pediatric niche market.

Technological Breakthrough Overcomes Critical Industry Pain Points

Pediatric nebulization therapy has long faced challenges such as material safety concerns,low patient compliance,and inconsistent drug absorption efficiency. HOMED Medical's R&D team has pioneered multiple core technologies specifically for children aged 0-6:

Smart Adaptive Nebulization System: Utilizes pressure sensors to monitor children's breathing rate in real time, dynamically adjusting nebulized particle size (precision control between 1-5μm) to elevate drug lung deposition rate to 85% (industry average approximately 55%);

Multi-Stage Filtration System: Incorporates internal recirculating air filtration, nano-sponge intake filtration, bacterial filtration at the device outlet, and convective gas bacterial filtration in the medication cup, ensuring every inhalation is clean and safe;

Ultra-Quiet Therapy: Utilizes 3D active holographic noise reduction technology to analyze, simulate, and suppress noise across the three-dimensional acoustic field, achieving targeted active noise cancellation. Ensures nebulizer operation noise does not exceed 45 decibels (industry average noise levels range from 60-70 decibels). Significantly improves children's treatment compliance.

"We are redefining the standard of pediatric nebulization therapy." stated Mr. Chen Yu, Executive Vice President of HOMED Medical. "Compared to traditional devices, our JLN-2311HDD Plus series features a soft silicone material that is skin-friendly and fits snugly on a child's face, ensuring they don't resist the treatment. With near-silent operation, the device eliminates fear, significantly boosting compliance. This effectively reduces treatment time and has slashed interruption rates due to crying from 47% to just 10%. To date, it has served over 2 million families.”

Building a New Ecosystem for Children's Health Management

In the future, HOMED Medical will deploy an intelligent early warning system in the field of home nebulization therapy. The company is developing an AI voiceprint analysis module to capture the acoustic characteristics of children's coughs, thereby constructing an early warning model for respiratory diseases covering pneumonia, asthma, and other pediatric respiratory conditions. Concurrently, it is developing integrated AR projection interactive games and VR diagnostic guidance systems. Children can enjoy immersive nebulization therapy, while parents receive immersive operational training. HOMED Medical will break down barriers between devices, services, and data. Over the next three years, it aims to reach 20 million children's households, enabling professional medical resources to enter home settings in a streamlined manner through AI technology.